This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Amicus, Amarin, Oncothyreon

Stocks in this article: FOLD ONTY AMRN

BOSTON ( TheStreet) -- This is the last Biotech Stock Mailbag for 2012. I've been writing this column for six years, but without your emails and tweets, the Mailbag wouldn't be possible. Thank you for all your comments, questions and criticism. Merry Christmas and Happy New Year. The Mailbag will return, rested and re-energized, in 2013.

@biotechmoney18 writes, "Hey, AF! Nice call on bullish $FOLD on 11/30. Maybe you should do some real DD instead of listening to your bleep boss."

I got Amicus Therapeutics (FOLD) wrong. I regret the bad call.

I expected Amicus' Fabry disease drug Amigal to demonstrate a statistically significant kidney response compared to placebo at six months -- the primary endpoint of the pivotal phase III study. Kidney response was defined as 50% reduction or more in kidney GL3 level at six months.

As reported Wednesday night, the 41% kidney response rate for Amigal patients surpassed the 28% response seen in placebo patients, but the difference was not statistically significant. The study failed. Amicus shares fell by nearly half Thursday.

The outcome is absolutely discouraging, and I'm not surprised to see the sharp selloff in Amicus. It's deserved. But I'm also unwilling to write off Amicus because the results of the study are just as frustrating and confusing as they are negative. There seems to be a signal of activity with Amigal that needs more detailed explanation. Unfortunately, Amicus chose not to hold a conference call to discuss the study results. I'll blame its partner GlaxoSmithKline (GSK) for that idiotic decision -- typical Big Pharma bull---t.

A full presentation of the Amigal study results is scheduled for the Lysosomal Disease Network World Symposium from Feb. 12 to 15.

The 28% response rate in placebo patients is much higher than expected. Why? Female Fabry patients have a lot more variability in GL3 levels, so this may have contributed to the miss. Two-thirds of the enrolled patients in the study were female, but we don't know the breakdown of female responders in each arm.

Lower-than-expected baseline GL3 levels (skewed toward the placebo patients) may also have played a role in boosting the placebo response rate higher than normal. Or, variability in the kidney biopsy samples, from which response is determined. Again, we don't know the answer but should get more clarity at the medical conference in February.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs